胃癌根治术联合SOX化疗方案对进展期胃癌患者预后的影响  

Effect of radical gastrectomy combined with SOX chemotherapy regimen on the prognosis of patients with advanced gastric cancer

作　　者：杨军[1] 崔颖[2] 赵健全 宋辉[1] YANG Jun;CUI Ying;ZHAO Jianquan;SONG Hui(Department of General Surgery,Qidong People’s Hospital,Jiangsu,Qidong 226200,China;Department of Oncology,Qidong People’s Hospital,Jiangsu,Qidong 226200,China)

机构地区：[1]江苏省启东市人民医院普外科,江苏启东226200 [2]江苏省启东市人民医院肿瘤科,江苏启东226200

出　　处：《中国医药科学》2022年第20期154-157,共4页China Medicine And Pharmacy

摘　　要：目的探讨胃癌根治术联合SOX化疗方案对进展期胃癌患者预后的影响。方法选取2016年1月至2018年12月100例启东市人民医院收治的进展期胃癌患者作为研究对象,采用随机数表法将纳入的患者分为SOX组(n=50)和DCF组(n=50),均接受胃癌根治术。DCF组患者采用多西他赛+顺铂+5-氟尿嘧啶(DCF方案辅助化疗),SOX组予以奥沙利铂+替吉奥(SOX方案辅助化疗)。比较两组的一般资料、围手术期指标、毒副反应程度、3年无进展生存率以及总生存率。结果两组一般资料、各项围手术期指标差异无统计学意义(P>0.05);化疗后,两组卡氏功能状态(KPS)评分均较化疗前升高(P<0.05);化疗后,SOX组KPS评分明显高于DCF组(P<0.05)。两组毒副反应程度比较,白细胞减少、血小板减少、贫血、腹泻、外周神经毒性、肝肾功能损害以及口腔黏膜炎差异均无统计学意义(P>0.05),SOX组恶心呕吐程度低于DCF组(P<0.05)。两组患者3年无进展生存率差异无统计学意义(P>0.05),SOX组3年总生存率为70.00%,明显高于DCF组的50.00%,差异有统计学意义(P<0.05)。结论进展期胃癌患者行根治术后联合采用SOX化疗方案更有利于患者预后,可有效提高患者生存率。Objective To investigate the effect of radical gastrectomy combined with S-1 and oxaliplatin(SOX)chemotherapy regimen on the prognosis of patients with advanced gastric cancer(AGC).Methods A total of 100 patients with AGC admitted to Qidong People’s Hospital from January 2016 to December 2018 were selected as study subjects,and the included patients were divided into SOX group(n=50)and DCF group(n=50)by random number table method,all of whom received radical gastrectomy.The patients in the DCF group were treated with docetaxel+cisplatin+5-fluorouracil(adjuvant chemotherapy in the DCF regimen),and the patients in the SOX group were treated with oxaliplatin+s igeo(adjuvant chemotherapy in the SOX regim en).The general information,perioperative indicators,degree of toxicity,3-year progression-free survival rate and overall survival rate were compared between the two groups.Results There were no statistically significant differences between the two groups in terms of general information and various perioperative indicators(P>0.05).The karnofsky performance status(KPS)scores in both groups increased after chemotherapy compared with those before chemotherapy(P<0.05).The KPS scores in the SOX group were significantly higher than those in the DCF group after chemotherapy(P<0.05).There were no statistically significant differences between the two groups in the degree of toxicities such as leukopenia,thrombocytopenia,anemia,diarrhea,peripheral neurotoxicity,liver and kidney function impairment,and oral mucositis(P>0.05),and the degree of nausea and vomiting in the SOX group was lower than that in the DCF group(P<0.05).There was no statistically significant difference between the two groups in 3-year progression-free survival rate(P>0.05),while the 3-year overall survival rate in the SOX group(70.00%)was significantly higher than that in the DCF group(50.00%),with statistically significant difference(P<0.05).Conclusion The combined use of SOX chemotherapy regimen following radical gastrectomy is conducive to improving the

关 键 词：根治术 SOX辅助化疗方案 进展期胃癌 预后 

分 类 号：R735.2[医药卫生—肿瘤]